CASI Pharmaceuticals (CASIF) Other Accumulated Expenses (2021 - 2025)

CASI Pharmaceuticals (CASIF) has 5 years of Other Accumulated Expenses data on file, last reported at $2.2 million in Q4 2025.

• Quarterly Other Accumulated Expenses rose 67.47% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (up 67.47% YoY) and the FY2025 annual result came in at $2.2 million, up 67.47% from the prior year.
• Other Accumulated Expenses declined to $2.2 million in Q4 2025, from $18.9 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $18.5 billion in Q1 2025 to a low of $519000.0 in Q4 2021.
• A 5-year average of $2.3 billion and a median of $1.8 million in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses surged 72.53% — and 2024, when it gained 19.32%.
• Tracing CASIF's Other Accumulated Expenses over 5 years: stood at $519000.0 in 2021, then gained by 24.86% to $648000.0 in 2022, then surged by 72.53% to $1.1 million in 2023, then increased by 19.32% to $1.3 million in 2024, then jumped by 67.47% to $2.2 million in 2025.
• The last three Other Accumulated Expenses figures came in at $2.2 million (Q4 2025), $18.9 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.